Latest stories on EVMN
Evommune price target lowered to $23 from $28 at Clear Street
The Fly38 · neutralanalyst
Stifel reiterates Evommune stock rating after phase 2b trial miss
Investing.com Analyst Ratings42 · neutralanalyst
Evommune price target lowered to $18 from $32 at Raymond James
The Fly34 · bearishanalyst
RBC cuts Evommune stock price target on drug trial setback
Investing.com Analyst Ratings32 · bearishanalyst
Evommune price target lowered to $21 from $29 at RBC Capital
The Fly34 · bearishanalyst
Evommune price target lowered to $22 from $28 at Leerink
The Fly38 · neutralanalyst
Evommune stock maintains Buy rating despite trial setback
Investing.com Analyst Ratings48 · neutralanalyst
Why is Evommune stock sliding 13% today?
Investing.com Markets34 · bearishgeneral
Evommune drops as eczema candidate fails in mid-stage trial
Seeking Alpha22 · bearishproduct/pr
Why is Evommune stock tumbling today?
Investing.com Markets34 · bearishgeneral
Why Is EVMN Stock Down 13% After-Hours?
Stocktwits News22 · bearishearnings
Evommune scraps eczema drug after trial miss, shares plunge
Reuters22 · bearishproduct/pr
Evommune Slides After Trial for Atopic Dermatitis Treatment Fails
MarketWatch32 · bearishproduct/pr
Evommune, Inc. (EVMN) files 8-K
SEC 8-K50 · neutralgeneral
Why is Evommune stock plunging today?
Investing.com Markets34 · bearishgeneral
Evommune down 31% at $9 after Phase 2b EVO-756 study results
The Fly34 · bearishearnings
Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints
The Fly22 · bearishproduct/pr
Evommune stock tumbles after trial misses primary endpoint
Investing.com Markets28 · bearishearnings
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
StockTitan63 · neutralproduct/pr
Evommune initiated with a Buy at Needham
The Fly61 · neutralanalyst
Evommune, Inc. GAAP EPS of -$0.89
Seeking Alpha53 · neutralearnings
Evommune price target lowered to $29 from $30 at RBC Capital
The Fly42 · neutralanalyst
Evommune Reports Q2 Eps 89c Consensus 67c
The Fly68 · bullishearnings
Evommune, Inc. (EVMN) files 8-K
SEC 8-K50 · neutralgeneral
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
StockTitan55 · neutralearnings